PET/Computed Tomography in Breast Cancer: Can It Aid in Developing a Personalized Treatment Design?
PET with fluorodeoxyglucose (FDG-PET)/computed tomography (CT) imaging has significantly improved the management of breast cancer. FDG, however, is not tumor-specific and various image interpretation pitfalls may occur due to false-positive and false-negative causes of FDG uptake. PET/CT imaging with more specific radiopharmaceuticals may provide useful information about the pathophysiology in such cases. In the present article, we reviewed the use of whole-body FDG-PET/CT and (18)F-16α-17β-Fluoroestradiol PET/CT imaging to determine if these can be used to develop personalized treatment design for the better management of breast cancer.
Department of Nuclear Medicine, Kasturba Medical College, Manipal University, SH 65, Manipal 576104, Karnataka, India.
Sumeet
S
Suresh Malapure
Diagnostic Nuclear Medicine Division, Department of Nuclear Medicine, All India Institute of Medical Sciences, Sri Aurobindo Marg, New Delhi 110029, India.
Kalpa Jyoti
KJ
Das
Diagnostic Nuclear Medicine Division, Department of Nuclear Medicine, All India Institute of Medical Sciences, Sri Aurobindo Marg, New Delhi 110029, India. Electronic address: rkphulia@yahoo.com.
Rakesh
R
Kumar
D001940:Breast / Q000000981:diagnostic imaging; D001943:Breast Neoplasms / Q000000981:diagnostic imaging*; D006801:Humans; D000072078:Positron Emission Tomography Computed Tomography; D057285:Precision Medicine / Q000379:methods*
(18)F-16α-17β-Fluoroestradiol PET/CT; (18)F-FDG PET/CT; Breast cancer; Receptor imaging